Besides traditional treatment strategies, including surgery, radiotherapy, and chemotherapy for lung cancer as the leading cause of cancer incidence and death, immunotherapy has also emerged as a new treatment strategy. The goal of immunotherapy is to stimulate the immune system responses against cancer, using various approaches such as therapeutic vaccines, monoclonal antibodies, immune checkpoint inhibitors, and T-cell therapy. Chimeric antigen receptor (CAR)-T cells, one of the most popular cancer immunotherapy approaches in the last decade, are genetically engineered T-cells to redirect patients' immune responses to recognize and eliminate tumor-associated antigens (TAA)-expressing tumor cells. CAR-T cell therapy provides promising benefits in lung tumors. In this review, we summarize different immunotherapy approaches for lung cancer, the structure of CAR-T cells, currently undergoing CARs in clinical trials, and various TAAs are being investigated as potential targets in designing CAR-T cells for lung cancer.

除了传统的治疗策略，包括肺癌的手术、放疗和化疗是导致癌症发病和死亡的主要原因，免疫疗法也成为一种新的治疗策略。免疫疗法的目标是刺激免疫系统对癌症的反应，使用各种方法，如治疗性疫苗、单克隆抗体、免疫检查点抑制剂和 T 细胞疗法。嵌合抗原受体 (CAR)-T 细胞是过去十年中最流行的癌症免疫治疗方法之一，它是一种基因工程 T 细胞，可重定向患者的免疫反应以识别和消除表达肿瘤相关抗原 (TAA) 的肿瘤细胞. CAR-T 细胞疗法在肺部肿瘤中提供了有希望的益处。在这篇综述中，我们总结了肺癌的不同免疫治疗方法，